DeNicola, Gina M
Chen, Pei-Hsuan
Mullarky, Edouard
Sudderth, Jessica A
Hu, Zeping
Wu, David
Tang, Hao
Xie, Yang
Asara, John M
Huffman, Kenneth E
Wistuba, Ignacio I
Minna, John D
DeBerardinis, Ralph J
Cantley, Lewis C
Article History
Received: 13 May 2015
Accepted: 23 September 2015
First Online: 19 October 2015
Change Date: 15 February 2016
Change Type: Correction
Change Details: In the version of this article initially published, the colors of the lines in the key in the top right corner of Figure 5h were incorrect. The line labeled "High" should be red and the line labeled "Low" should be blue. The error has been corrected in the HTML and PDF versions of the article.
Competing interests
: L.C.C. owns equity in, receives compensation from and serves on the Board of Directors and Scientific Advisory Board of Agios Pharmaceuticals. Agios Pharmaceuticals is identifying metabolic pathways in cancer cells and developing drugs to inhibit such enzymes to disrupt tumor cell growth and survival. R.J.D. is on the scientific advisory boards of Agios Pharmaceuticals and Peloton Therapeutics. Peloton Therapeutics is developing drugs to target altered molecular pathways in cancer, including altered metabolism.